PFE - Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today? | Benzinga
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights utilized in Comirnaty, BioNTech, and Pfizer Inc's (NYSE: PFE) mRNA COVID-19 vaccine.
The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights.
Proceedings continue regarding the seven remaining rights, for which validity, infringement, and potential damages will be decided individually.
Following ...